Studies of other MET tyrosine kinase inhibitors, such as crizotinib, cabozantinib, and capamatinib, for pancreatic cancer have suggested that trametinib may be effective in treating pancreatic cancer. This evidence concerns the gene MET and familial pancreatic carcinoma.